ASX:ALA Arovella Therapeutics (ALA) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free ALA Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield1.23%Price TargetN/A Stock AnalysisStock Analysis Get Arovella Therapeutics alerts: Email Address Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Arovella TherapeuticsArovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.Read More Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide ALA Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive ALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arovella Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:ALA CUSIPN/A CIKN/A Webwww.arovella.com Phone61 8 6142 5555FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,230,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-276.74% Return on Assets-98.07% Debt Debt-to-Equity Ratio0.87 Current Ratio2.37 Quick Ratio4.05 Sales & Book Value Annual Sales$1.97 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares925,160,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.67 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Michael BakerCEO, MD & DirectorDr. Nicole van der Weerden B.Sc.BSc (Hons), MBA (MBS), Ph.D., Chief Operating OfficerMr. Tim Luscombe B.Com.C.A., Company Secretary & CFOMichelle LongAdministration ManagerTony MacintyreGM & CTOKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersMichael BakerBought 220,000 shares on 3/27/2024Total: $31,240.00 ($0.14/share)Michael BakerBought 587,824 shares on 12/29/2023Total: $67,599.76 ($0.12/share)Thomas (Tom) DuthySold 6,521,739 sharesTotal: $299,999.99 ($0.05/share)Thomas (Tom) DuthySold 444,444 sharesTotal: $19,999.98 ($0.05/share)Elizabeth StonerSold 500,000 sharesTotal: $10,000.00 ($0.02/share) This page (ASX:ALA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arovella Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
